EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudie

Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study

Lingfang Xia, Keqiang Zhang, Ying Tang, Guonan Zhang, Danbo Wang, Hanmei Lou, Naifu Liu, Hongping Zhang, Hongwei Chen, Ke Wang, Shuqing Wei, Li Wang iD und 25 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-24-02495 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Lingfang Xia und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Uterine Cervical Neoplasms, Antibodies, Monoclonal, Humanized, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To compare camrelizumab (an anti-PD-1 monoclonal antibody) plus famitinib (a multitarget receptor tyrosine kinase inhibitor) versus camrelizumab and chemotherapy in recurrent or metastatic cervical cancer (R/M CC). METHODS Patients with pretreated R/M CC were randomly assigned to receive camrelizumab (200 mg intravenously once every 3 weeks) plus famitinib (20 mg orally once daily), camrelizumab, or investigator's choice of chemotherapy. The primary end point was comparison of objective response rate (ORR) per blinded independent central review (BICR) for camrelizumab-famitinib versus camrelizumab in the intention-to-treat population. RESULTS Overall, 105, 54, and 35 patients received camrelizumab-famitinib, camrelizumab, and chemotherapy, respectively. As of April 21, 2023, ORR per BICR was significantly improved with camrelizumab-famitinib compared with camrelizumab (41.0% [95% CI, 31.5 to 51.0] v 24.1% [95% CI, 13.5 to 37.6]; difference, 16.9% [95% CI, 2.1 to 31.7]; one-sided P = .0181). Per investigator, ORR with camrelizumab-famitinib was 42.9% (95% CI, 33.2 to 52.9), notably higher than 22.2% (95% CI, 12.0 to 35.6) with camrelizumab and 14.3% (95% CI, 4.8 to 30.3) with chemotherapy. Median progression-free survival per investigator was prolonged with camrelizumab-famitinib than camrelizumab and chemotherapy (8.1 months [95% CI, 6.2 to 12.4] vs 4.1 months [95% CI, 2.1 to 5.1] and 2.9 months [95% CI, 2.0 to 6.2]). Median overall survival with camrelizumab-famitinib, camrelizumab, and chemotherapy, as of October 19, 2023, was 20.2 months (95% CI, 15.3 to not reached [NR]), 14.9 months (95% CI, 12.6 to NR), and 13.9 months (95% CI, 7.4 to 20.0), respectively. Eighty-nine (84.8%), eight (15.1%), and 18 (60.0%) patients who received camrelizumab-famitinib, camrelizumab, and chemotherapy, respectively, experienced grade ≥3 treatment-related adverse events. CONCLUSION Camrelizumab plus famitinib improved antitumor activity while exhibiting a manageable safety profile in patients with pretreated R/M CC, potentially offering a novel treatment option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsUterine Cervical NeoplasmsAntibodies, Monoclonal, HumanizedNeoplasm Recurrence, LocalHumansFemaleMiddle AgedAdultAged

Substanzen

camrelizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Gynecologic Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • Department of Gynecologic Oncology, Chongqing University Cancer Hospital, Chongqing, China.
  • Department of Gynecology Oncology, Sichuan Cancer Hospital, Chengdu, China.
  • Department of Gynecology, Liaoning Cancer Hospital and Institute, Shenyang, China.
  • Department of Gynecological Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, China.

ORCID-Profile: Li Wang, Hong Zhu, Xiaohua Wu

Zitieren

APA

Xia, L., Zhang, K., Tang, Y., Zhang, G., Wang, D., Lou, H., Liu, N., Zhang, H., Chen, H., Wang, K., Wei, S., Wang, L., Gao, K., Li, G., Zhang, H., Hu, Y., Zhao, W., Zhang, Y., Zhu, H., …, & Wu, X. (2025). Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-02495

Vancouver

Xia L, Zhang K, Tang Y, Zhang G, Wang D, Lou H, et al. Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-02495

BibTeX
@article{Xia2025,
  author = {Xia, Lingfang and Zhang, Keqiang and Tang, Ying and Zhang, Guonan and Wang, Danbo and Lou, Hanmei and Liu, Naifu and Zhang, Hongping and Chen, Hongwei and Wang, Ke and Wei, Shuqing and Wang, Li and Gao, Kun and Li, Guiling and Zhang, Huifeng and Hu, Yuanjing and Zhao, Weidong and Zhang, Yunyan and Zhu, Hong and Lin, An and Miao, Jinwei and Yu, Guohua and Hua, Keqin and Tang, Liangdan and Liu, Ziling and Zhang, Bingzhong and Li, Hongwei and Zheng, Min and Wang, Xiaohong and Li, Fenghu and Yang, Xinfeng and Zhou, Huaijun and Xia, Bairong and Zhou, Xianfeng and Wang, Yuting and Wang, Quanren and Wu, Xiaohua},
  title = {Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-24-02495}
}
Kostenlos starten →